Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations
Conclusion:
The results suggested that treatment with FDC AML/OM was associated with greater likelihood of adherence and lower overall costs than with FDC AML/BEN and LDC AML/ARB, and lower risk of cardiovascular event composite versus LDC AML/ARB.
Source: Therapeutic Advances in Cardiovascular Disease - Category: Cardiology Authors: Ferrario, C. M., Panjabi, S., Buzinec, P., Swindle, J. P. Tags: Original Research Source Type: research
More News: Benazepril | Cardiology | Cardiovascular | Heart | Hypertension | Lotrel | Norvasc | Study